AMICUS THERAPEUTICS, INC. — Director's Dealing 2023

Mar 3, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2023-03-01

Reporting Person: Campbell Bradley L (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-01	Common Stock	M	11700	$2.45	Acquired	856829	Direct
2023-03-01	Common Stock	S	15456	$13.1156	Disposed	841373	Direct
2023-03-01	Common Stock	S	4544	$13.6766	Disposed	836829	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-03-01	Stock Options (right to buy)	$2.45	M	11700	Disposed	2024-01-03	Common Stock (11700)	Direct

Footnotes

F1: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.62 to $13.61 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.62 to $13.82. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: All of the options were fully vested and exercisable as of the transaction date.